Research & Development
A New Generation of Vaccines
Etubics
is developing innovative immunotherapies and vaccines, utilizing our
exclusive Adenovirus Vector Vaccines Platform (AVVP) technology and our
patented human E.C7 human cell line, together the Etubics Platform. The
Etubics Platform delivers a long lasting "active" immune response
against a wide range of diseases. It has been proven to be safer, more
efficient and more effective than current vectored vaccines and gene
delivery platforms.
Etubics has recently completed early
stage clinical trials with ETBX-011, an immunotherapy for late-stage
metastatic colorectal cancer.
Etubics is currently
developing products to treat or protect against the following diseases:
Therapeutic Vaccines
Preventative Vaccines